創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
18/09/20 GEM042 TLR4 antagonist NAFLD, AIH, CLD and CD Oral Small molecules
Phase 2 NAFLD (nonalcoholic fatty liver disease): The phase 2 results demonstrated significant improvement on relevant diagnosis and biomarkers.
AIH (autoimmune hepatitis; orphan designation): The phase 2 (open label) results will be available soon.
CLD(chronic liver disease by HCV infection): A strong trend of improvement of liver function and safety in Phase 2.
CD (Crohn's disease): Good efficacy in three Phase 2 POC studies.
The drug is safe and tolerable in these trials.
Can be licensed to territories except Asia
問合せ
18/09/20 GEM041 Dual inhibitor of catechol-O-methyltransferase and dopa decarboxylase Parkinson's disease Oral Small molecules
Preclinical First dual inhibitor in the World.
Almost same inhibitory activities for the two enzymes.
The enzyme activities were inhibited strongly in the liver, but not in the brain.
問合せ
18/08/31 GEM040 Topical anti-inflammatory Joint pain, Muscle pain, Gout, Local inflammatory pain see Note Small molecules
Preclinical Topical formulations of Ibuprofen, Naproxen, Diclofenac to use in the treatment of inflamatory pain and related conditions
Formulation shows 5 to 10X increase human skin permeation coupled
Potential for OTC or RX introduction: minimal development timeline

Route:Topical
問合せ
18/08/31 GEM039 Antifungal Onychomy- cosis see Note Small molecules
Preclinical Novel and unique topical formulation of Terbenafine with exceptional permeation (40 fold) across the human nail.
Potential for OTC or RX introduction: minimal development timeline

Indication:Onychomycosis
Route:Topical
問合せ
18/08/31 GEM038 Locally acting anti-inflammatory- Trigeminal neuro-inflammation Migraine Local Small molecules
Phase 2a Clinical POC in acute migraine therapy in Phase 2a
Efficacy comparable to Triptans but with no systemic side effects or restrictions
Shortened development timelines (NDA:2021)
Product opportunity for use in Temporomandibular Joint Disease and trigeminal neuralgias
問合せ
18/08/31 GEM037 Allosteric modulator of the CCR3 receptor Asthma, rhinitis Oral Small molecules
Phase 2a In phase 2a:
Highly significant effects on the methacholine provocative response
Showed trends to improvement in EAR (Early Phase Allergic Response)
Reduced induced sputum eosinophil percentage and increased percent blood eosinophil
問合せ
18/08/27 GEM036 Hematopoietic stem cell fucosylation Prevention of infection & GvHD from hematopoietic stem cell transplantation see Note Proteins
Phase 3 ready with FDA SPA In Phase II study:
Statistically significant acceleration of immune system reconstitution
(neutrophil/platelet recovery)
Significantly reduced infection and GvHD
Improved survival
Positioned to be best-in-classNo
reports of adverse event specifically attributable to fucosylation

Route:Infusion
問合せ
18/08/07 GEM035 An anti-ENO1 antibody Immune diseases, various cancers SC Proteins
Preclinical (close to IND) Showed efficacy in animal models of multiple sclerosis, RA, pancreatic cancer and liver cancer.
Also applicable to IBD and COPD etc.
Completed pre-clinical studies including monkey toxicity studies, GMP production.
問合せ
18/08/07 GEM034 Derivative of neuroprotective protein Stroke, Huntington chorea, Schizophrenia and PTSD IV Peptides
Preclinical A cell-permeable recombinant peptide.
Can cross the blood-brain barrier, is resistant to degradation, and can bind constitutively to its substrates.
Significantly reduces brain damage in rodent stroke model.
Expected to be treated after stroke without diagnosis of stroke type before dosing.
問合せ
18/08/07 GEM033 Inhibitors of bacterial resistance mechanisms Gram-negative MDR bacterial infections, lung infections in cystic fibrosis (CF) patients see Note Small molecules
Preclinical Restore effectiveness of shelved antibiotics.
Lower the effective dose of antibiotics.
Mitigate antibiotic resistance.
Disrupt biofilm-based infections.
Over 1,000 compounds with lead compounds for each indication identified.

Route : Intravenous, Aerosol, Topical
問合せ